Navigation Links
Gene therapy cures a severe paediatric neurodegenerative disease in animal models
Date:7/2/2013

Sanfilippo Syndrome type A, or Mucopolysaccharidosis type IIIA (MPSIIIA), is a neurodegenerative disease caused by mutations in the gene that encodes the enzyme sulfamidase. Mutations in this gene lead to deficiencies in the production of the enzyme, which is essential for the breakdown of substances known as glycosaminoglicans. If these substances are not broken down, they accumulate in the cells and cause neuroinflammation and organ dysfunction, mainly in the brain, but also in other parts of the body. Children born with this mutation are diagnosed from the age of 4 or 5. They suffer neurodegeneration, causing mental retardation, aggressiveness, hyperactivity, sleep alterations, loss of speech and motor coordination, and they die in adolescence.

A team of researchers headed by the director of the UAB's Centre for Animal Biotechnology and Gene Therapy (CBATEG), Ftima Bosch, has developed a gene therapy treatment that cures this disease in animal models, with pre-clinical studies in mice and dogs. The treatment consists of a single surgical intervention in which an adenoassociated viral vector is injected into the cerebrospinal fluid, the liquid that surrounds the brain and the spinal cord. The virus, which is completely harmless, genetically modifies the cells of the brain and the spinal cord so that they produce sulfamidase, and then spreads to other parts of the body, like the liver, where it continues to induce production of the enzyme.

Once the enzyme's activity is restored, glycosaminoglican levels return to normal for life, their accumulation in cells disappears, along with the neuroinflammation and dysfunctions of the brain and other affected organs, and the animal's behaviour and its life expectancy return to normal. While mice with the disease lived only up to 14 months, those given the treatment survived as long as healthy ones.

This is a joint project between the UAB and the pharmaceutical company Esteve. The study has
'/>"/>

Contact: Fàtima Bosch
Fatima.bosch@uab.cat
34-935-814-182
Universitat Autonoma de Barcelona
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Pufferfish neurotoxin may serve as treatment for cancer therapy related pain
2. A circuitous route to therapy resistance
3. Vein Therapy News Magazine Publishes Laser Facelift Article by Dr. Robin Fleck
4. Rural women less likely to get radiation therapy after lumpectomy for breast cancer
5. New understanding of why anti-cancer therapy stops working at a specific stage
6. Past Life Regression Therapy: Valid Treatment or Ridiculous Foo Foo; Researcher and Author Dr. Heather Friedman Rivera on Dr. Carol Francis Radio Talk Show
7. Genetics of cervical cancer raise concern about antiviral therapy in some cases
8. PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network
9. June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy
10. Filtersfast.com Launches Spazazz Aromatherapy Spa & Bath Crystals
11. Newly Released Continuing Education Courses Provide Physical and Occupational Therapy Professionals With Opportunities To Expand Skill Sets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... young children to embrace a more healthful diet? ... them. Doing so will actually make them think it ... and caregivers who are struggling to get children to ... food without saying anything about it, or (if credible) ... authors Michal Maimaran, of Northwestern University,s Kellogg School of ...
(Date:7/29/2014)... claims for cosmetic procedures using stem cells are running ... effectiveness, according to a review in the August issue ... the official medical journal of the American Society ... tremendous potential, but the marketplace is saturated with unsubstantiated ... risk," write Dr Michael T. Longaker of Stanford University ...
(Date:7/29/2014)... the bite of a brown recluse spider is poisonous, ... expert notes. It,s still important to recognize the ... recluse spider bite, warned Dr. Donna Seger, medical director ... dangerous bites are on the rise. "As physicians, ... [bite] has classic characteristics, but if physicians are not ...
(Date:7/29/2014)... Nevada (PRWEB) July 29, 2014 The Board ... Holland & Hart LLP ’s Connie Akridge ... She currently serves as President of the Foundation. Akridge served ... , Akridge is a partner at Holland & Hart in ... litigation and regulatory/administrative matters to insurance and healthcare clients for ...
(Date:7/29/2014)... Many people complain about their dependence on eyeglasses. For ... put on glasses to see their clock or make their ... be dissatisfied with their vision even when using their glasses ... driving, especially at night due to glare. They can ... see the TV, sew or cross stitch, or read fine ...
Breaking Medicine News(10 mins):Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2
... home care which is advantageous for people with ... obstructive pulmonary disease (COPD) - can be very disabling, ... study from researchers at Barcelona// Hospital, Spain, shows that ... the home setting cuts costs, re-admission to hospital and ...
... a device that filters toxins from the blood can buy ... failure is a relatively common problem and most often the ... short supply and many patients die while waiting for one. ... many years now, but the liver is such a complex ...
... a new study, weight loss followed by weight gain is ... health risks of obesity are now well established to many. ... some studies have suggested that fluctuating weight may, in itself, ... ,Researchers in London studied a group of 5,428 middle-aged British ...
... cystitis depends upon how their condition is diagnosed according ... the bladder which leads to frequent urination,// incomplete emptying ... It's common among women and can greatly impair their ... University of Bergen, Norway, describes a new approach to ...
... a new research, people with severe respiratory disease can walk ... as they exercise. Exercise is key to pulmonary// rehabilitation in ... increase the distance they can walk in a fixed time ... ,Researchers at Ohio State University now report on ...
... regarding the do's and dont's of dieting. Nutrition experts at ... through the dieting controversy.// We've been discussing and arguing over ... - for many decades now, and still the obesity 'epidemic' ... Green Mountain in the US suggest a new approach - ...
Cached Medicine News:
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- The global ... of products, methods, applications, end users, and geographies. ... in the microbial identification market. This favorable growth ... (per test) and the time required for microbial ... technological advancements. Furthermore, genotypic methods have high applications ...
(Date:7/29/2014)... THOUSAND OAKS, Calif., July 29, 2014 Amgen ... for the second quarter of 2014. Key results include: ... million, with 8 percent product sales growth driven by ... (etanercept), Kyprolis ® (carfilzomib), Prolia ® (denosumab) ... grew 25 percent to $2.37, driven by higher revenues ...
(Date:7/29/2014)... LOUIS, July 29, 2014  Express Scripts Holding Company ... net income attributable to Express Scripts stockholders of $515.2 ... diluted share, as detailed in Table 4, was $1.23 ... are well positioned to serve our clients with scale, alignment ... to improve the health outcomes of our members," stated George ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7
... , DETROIT, Dec. 30 For the twelfth ... Church of Christ, is campaigning to save lives during New ... for the New Millennium, Health Alliance Plan (HAP) and the ... residents to celebrate the New Year without gunfire. The ...
... BOSTON, Dec. 30 Solos Endoscopy, Inc. (Pink Sheets: SNDY) ... prosperous 2010, following a solid year in 2009, due in great ... months of 2009, Solos Endoscopy, Inc. has taken the initial steps ... endoscopy instruments. This will allow the MammoView(TM) line to be sold ...
Cached Medicine Technology:Rev. Nick Hood, III Asks Southeast Michiganders Not to Use Guns During New Year's Eve Celebrations 2Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010 2
The NIAGARA Thermal Retention System (TRS) maintains the temperature of prewarmed irrigation fluid continuously as it is delivered through the Corson®, Surgiflex® WAVE™, or Surgiflex D...
... Sur-Catch NT stone retrieval basket raises proven tipless, ... unique paired wire design and multi-sizing basket enable ... of each patient and procedure. Its highly ... with the DURTM-8 Elite Ureteroscope and its ergonomic ...
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
Medicine Products: